Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 4.70
INFI's Cash-to-Debt is ranked lower than
62% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. INFI: 4.70 )
Ranked among companies with meaningful Cash-to-Debt only.
INFI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.93  Med: 64.27 Max: No Debt
Current: 4.7
Piotroski F-Score: 3
Altman Z-Score: -3.58
Beneish M-Score: -4.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -111.11
INFI's Operating Margin % is ranked lower than
51% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. INFI: -111.11 )
Ranked among companies with meaningful Operating Margin % only.
INFI' s Operating Margin % Range Over the Past 10 Years
Min: -164.99  Med: -91.69 Max: 22.94
Current: -111.11
-164.99
22.94
Net Margin % -108.27
INFI's Net Margin % is ranked lower than
52% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. INFI: -108.27 )
Ranked among companies with meaningful Net Margin % only.
INFI' s Net Margin % Range Over the Past 10 Years
Min: -160.77  Med: -68.67 Max: 28.35
Current: -108.27
-160.77
28.35
ROE % -33.60
INFI's ROE % is ranked higher than
54% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. INFI: -33.60 )
Ranked among companies with meaningful ROE % only.
INFI' s ROE % Range Over the Past 10 Years
Min: -123.36  Med: -33.2 Max: 27.59
Current: -33.6
-123.36
27.59
ROA % -15.14
INFI's ROA % is ranked higher than
65% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. INFI: -15.14 )
Ranked among companies with meaningful ROA % only.
INFI' s ROA % Range Over the Past 10 Years
Min: -44.77  Med: -21.57 Max: 16.29
Current: -15.14
-44.77
16.29
ROC (Joel Greenblatt) % -111.27
INFI's ROC (Joel Greenblatt) % is ranked higher than
64% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. INFI: -111.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INFI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3156.78  Med: -543.5 Max: 418.86
Current: -111.27
-3156.78
418.86
3-Year EBITDA Growth Rate -39.50
INFI's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. INFI: -39.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INFI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.4  Med: 4.45 Max: 135.8
Current: -39.5
-55.4
135.8
3-Year EPS without NRI Growth Rate -38.60
INFI's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. INFI: -38.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INFI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64  Med: 12.3 Max: 116
Current: -38.6
-64
116
GuruFocus has detected 3 Warning Signs with Infinity Pharmaceuticals Inc $INFI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INFI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

INFI Guru Trades in Q1 2016

Paul Tudor Jones 59,600 sh (New)
Steven Cohen Sold Out
Jim Simons 12,300 sh (-92.22%)
Eaton Vance Worldwide Health Sciences Fund 654,534 sh (-3.46%)
» More
Q2 2016

INFI Guru Trades in Q2 2016

Jim Simons 749,700 sh (+5995.12%)
Paul Tudor Jones 277,600 sh (+365.77%)
Eaton Vance Worldwide Health Sciences Fund Sold Out
» More
Q3 2016

INFI Guru Trades in Q3 2016

Jim Simons 1,860,900 sh (+148.22%)
Paul Tudor Jones 19,798 sh (-92.87%)
» More
Q4 2016

INFI Guru Trades in Q4 2016

Paul Tudor Jones 165,998 sh (+738.46%)
Jim Simons 1,700,000 sh (-8.65%)
» More
» Details

Insider Trades

Latest Guru Trades with INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:IMDZ, AMEX:OCX, NAS:CBMG, NAS:GNCA, NAS:KIN, NAS:MDGL, NYSE:KDMN, NAS:CLSD, NAS:RDHL, NAS:NYMX, OTCPK:VNLPY, NAS:VBLT, NAS:MNKD, NAS:FBIO, NAS:REPH, AMEX:AST, NAS:KURA, OTCPK:ATVBF, NAS:QURE, NAS:ABUS » details
Traded in other countries:I3F.Germany,
Infinity Pharmaceuticals Inc is a biopharmaceutical company engaged in discovering, developing & delivering medicines to people with difficult-to-treat diseases. Its primary product candidate is duvelisib, also known as IPI-145, an oral inhibitor.

Infinity is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products, and those under development, include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments.

Top Ranked Articles about Infinity Pharmaceuticals Inc

Pernix: An Investor's Rationale to Staying Long The stock has fallen a bit, but there's a good reason investors are staying long
I am letting you know from the beginning, I am long Pernix Therapeutics Holdings Inc. (NASDAQ:PTX). While I may have gotten to the point where I play hide-and-seek with the daily share price fluctuations, I am far from throwing in the towel on this company. I am not stubborn to the point of becoming poor, nor do I enjoy frequent episodes of pain. Rather, I tend to have the ability to cut through the minutiae and get to the nitty gritty of the issue at hand. As such, despite Pernix's current issues, I still see significant upside value. Read more...

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 3.73
INFI's Price-to-Owner-Earnings is ranked higher than
94% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 31.38 vs. INFI: 3.73 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
INFI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.02  Med: 9.33 Max: 154.41
Current: 3.73
1.02
154.41
PB Ratio 2.06
INFI's PB Ratio is ranked higher than
73% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. INFI: 2.06 )
Ranked among companies with meaningful PB Ratio only.
INFI' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 3.11 Max: 51.43
Current: 2.06
0.45
51.43
PS Ratio 6.01
INFI's PS Ratio is ranked higher than
70% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. INFI: 6.01 )
Ranked among companies with meaningful PS Ratio only.
INFI' s PS Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.82 Max: 60.95
Current: 6.01
0.55
60.95
Current Ratio 4.26
INFI's Current Ratio is ranked higher than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. INFI: 4.26 )
Ranked among companies with meaningful Current Ratio only.
INFI' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 7.3 Max: 17.67
Current: 4.26
0.67
17.67
Quick Ratio 4.26
INFI's Quick Ratio is ranked higher than
54% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. INFI: 4.26 )
Ranked among companies with meaningful Quick Ratio only.
INFI' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 7.11 Max: 17.67
Current: 4.26
0.53
17.67
Days Sales Outstanding 1.12
INFI's Days Sales Outstanding is ranked higher than
97% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. INFI: 1.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
INFI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.18  Med: 2.82 Max: 75.87
Current: 1.12
0.18
75.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.50
INFI's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. INFI: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INFI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -178.7  Med: -10.5 Max: -0.8
Current: -1.5
-178.7
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.49
INFI's Price-to-Net-Cash is ranked higher than
72% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. INFI: 3.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INFI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.1  Med: 3.5 Max: 38.43
Current: 3.49
1.1
38.43
Price-to-Net-Current-Asset-Value 2.92
INFI's Price-to-Net-Current-Asset-Value is ranked higher than
74% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. INFI: 2.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INFI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.87  Med: 3.08 Max: 26.79
Current: 2.92
0.87
26.79
Price-to-Tangible-Book 2.07
INFI's Price-to-Tangible-Book is ranked higher than
79% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. INFI: 2.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INFI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76  Med: 3.18 Max: 15.29
Current: 2.07
0.76
15.29
Price-to-Median-PS-Value 1.58
INFI's Price-to-Median-PS-Value is ranked lower than
82% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. INFI: 1.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INFI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.86 Max: 5.23
Current: 1.58
0.15
5.23
Earnings Yield (Greenblatt) % -29.36
INFI's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. INFI: -29.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INFI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -31.11  Med: 80.85 Max: 857.3
Current: -29.36
-31.11
857.3

More Statistics

Revenue (TTM) (Mil) $27.80
EPS (TTM) $ -0.62
Beta2.57
Short Percentage of Float10.73%
52-Week Range $0.84 - 6.63
Shares Outstanding (Mil)50.43

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 90 55
EPS ($) -1.34 -0.76 -0.76
EPS without NRI ($) -1.34 -0.76 -0.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for INFI

Headlines

Articles On GuruFocus.com
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 
Infinity Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
ETFs with exposure to Infinity Pharmaceuticals, Inc. : March 27, 2017 Mar 27 2017
3 Reasons Why Infinity Pharmaceuticals (INFI) is a Great Momentum Stock Mar 23 2017
Infinity Pharma Focuses on Cancer Drug: Competition Looms Mar 21 2017
Infinity Pharmaceuticals, Inc. :INFI-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017 Mar 20 2017
INFINITY PHARMACEUTICALS, INC. Financials Mar 18 2017
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4 Mar 15 2017
Infinity reports 4Q loss Mar 14 2017
Infinity reports 4Q loss Mar 14 2017
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 14 2017
Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results Mar 14 2017
INFINITY PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 14 2017
Q4 2016 Infinity Pharmaceuticals Inc Earnings Release - After Market Close Mar 14 2017
IPI-549 Featured at 15th International Congress on Targeted Anticancer Therapies Mar 06 2017
Infinity Announces Presentation on IPI-549 at AACR Annual Meeting Mar 02 2017
Infinity Pharmaceuticals (INFI) Catches Eye: Stock Up 13.5% Mar 01 2017
Infinity Announces the Date of Its Full-Year 2016 Financial Results Conference Call and Webcast Feb 28 2017
Infinity to Present at 37th Annual Cowen and Company Healthcare Conference Feb 27 2017
Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer Feb 13 2017
Infinity to Present at the 2017 BIO CEO & Investor Conference Feb 06 2017
Faster FDA Approval Process Could Ignite These Biotech Stocks in 2017 Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)